Cyanotic ACHD

Cyanotic heart disease comprises a heterogeneous group of congenital heart defects characterized by hypoxemia and central cyanosis resulting from right-to-left shunting. Clinically, cyanosis appears as a bluish discoloration of the skin and/or mucous membranes, though it may be difficult to detect in patients with anemia or dark skin pigmentation.

Secondary erythrocytosis is a normal physiological response that helps maintain optimal hemoglobin and hematocrit levels.

However, increases in red cell mass deplete bone marrow iron stores, leading to iron-deficiency anemia.

Iron-deficiency anemia impairs systemic oxygen transport, clinically manifesting as exercise intolerance, transient ischemic attacks, stroke, and myocardial ischemia. Patients with ACHD and cyanosis may also present with symptoms of hyperviscosity, such as headache and visual disturbances.

Cyanosis is associated with alterations in the coagulation cascade, resulting in both hypo- and hypercoagulable states and leading to increased risks of bleeding (hemoptysis, epistaxis) and thrombosis (transient ischemic attack/stroke, pulmonary embolism).

Chronic cyanosis affects multiple organ systems and may manifest as kidney dysfunction and proteinuria, hypertrophic osteoarthropathy, myocardial dysfunction, neurologic impairment, and hypertensive emergencies secondary to neuroendocrine tumors such as pheochromocytomas and paragangliomas.

Recommendation-Specific Supportive

Routine screening and treatment of iron deficiency are recommended, as deficiency may occur despite normal or elevated hematocrit and its treatment improves exercise capacity and quality of life.

Patients with ACHD and cyanosis, particularly those with Eisenmenger syndrome, are at increased risk of stroke and brain abscess; new or worsening headache or neurologic symptoms warrant urgent brain imaging.

Hyperviscosity syndrome should be suspected in symptomatic patients with hematocrit >65% after exclusion of acute neurologic events; most respond to rehydration and treatment of iron-deficiency anemia.

In patients with ACHD and cyanosis, pregnancy carries high cardiovascular and obstetric risk, but multidisciplinary care during and after pregnancy (excluding those with Eisenmenger syndrome) is associated with reduced cardiovascular complications compared with historical data.

Pregnancy-related cardiovascular, obstetric, and neonatal risks rise with CHD complexity and are higher in cyanotic patients; estrogen-containing contraceptives increase thromboembolic risk and should be avoided in ACHD with cyanosis.

ACHD patients with cyanosis have a higher prevalence of pheochromocytomas and paragangliomas; those with episodes of tachycardia or hypertension should undergo screening with plasma and 24-hour urinary fractionated metanephrines.

Hyperuricemia is common in ACHD with cyanosis; joint pain in these patients should prompt evaluation for gout.

Supplemental oxygen during exercise improves exercise capacity compared with ambient air.

Phlebotomy (removal of 250–500 mL of blood with equal isotonic fluid replacement) may be used for refractory hyperviscosity symptoms after adequate hydration and correction of iron deficiency, but prophylactic phlebotomy should be avoided because it worsens iron deficiency and increases stroke risk.

References

1) Gurvitz M, Krieger EV, Fuller S, Davis LL, Kittleson MM, Aboulhosn JA, Bradley EA, Buber J, Daniels CJ, Dimopoulos K, Egbe A, Geoffrion TR, John A, Khairy P, Kim YY, Kreutzer J, Lewis MJ, Menachem JN, Moore JP, Osteen KA, Parikh PB, Saidi A, Salciccioli KB, Schunder RL, Valente AM, Wald RM. 2025 ACC/AHA/HRS/ISACHD/SCAI Guideline for the Management of Adults With Congenital Heart Disease: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. 2026 Feb 24;87(7):822-976. doi: 10.1016/j.jacc.2025.09.006. Epub 2025 Dec 18. PMID: 41411480.